MENU
Articles by #hashtag

Pharmaceutical industry

39 hits

Richter: Faster Than Expected Growth in the 2nd Quarter

D&T
Aug 3, 2022

In the second quarter of this year, the Hungarian pharmaceutical company Gedeon Richter's sales and profit exceeded analysts' expectations: sales increased by 23.7% to HUF 192.9 billion and profit after tax more than doubled to HUF 77.1 billion in April-June compared to the same period last year, the company said on the website of the […]

Egis To Further Develop Infrastructure in Körmend

D&T
Jun 18, 2022

As part of the continuation of a series of large-scale developments since 2019, leading pharmaceutical giant Egis Gyógyszergyár Plc. now invests EUR 21.1 million in Körmend, W Hungary to install new technology, increase capacity and enhance efficiency. The investment is set to help the company not only produce more but also adapt to rapidly changing […]

Richter Announces Evra Distribution in Canada

D&T
May 12, 2022

Gedeon Richter Plc. and Searchlight Pharma Inc. have announced that Searchlight has assumed all Canadian distribution and promotional activities for Evra®, a transdermal contraceptive patch. This transition, which covers regulatory, distribution and promotional responsibilities in Canada, stems from the acquisition of ex-US rights to the Evra brand by Richter from Janssen Pharmaceutica NV, a wholly-owned […]

New Cooperation Between AbbVie and Gedeon Richter

D&T
Mar 12, 2022

AbbVie and Gedeon Richter Plc. have announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development. AbbVie and Richter […]

Application to FDA for Further Use of Cariprazine

D&T
Feb 22, 2022

AbbVie, the partner company of the Hungarian pharmaceutical firm Gedeon Richter Plc., has submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR®) to the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy. The submission is supported by results from […]

Vaccinating Animals Also Protects Humans

Sándor Laczkó
Jan 15, 2022

It was announced this late November that Ceva Phylaxia will set up a new vaccine factory along with the associated infrastructure by developing a new site under a greenfield investment in Hungary. As the General Manager of the company, Dr. Zsolt Németh tells Diplomacy&Trade, Ceva Phylaxia is growing and planning to grow. “Investments related to […]

A New Leading European Company

Sándor Laczkó
Jan 7, 2022

Early this year, the French multinational healthcare company Sanofi announced the establishment of EUROAPI, a future leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients (API). The standalone company will combine Sanofi’s API commercial and development activities with six of its European production sites, one of which is in Újpest, […]

Roche Hungary Signs Strategic Cooperation Agreement

D&T
Dec 4, 2021

One of the largest companies in the healthcare industry, Roche Hungary Ltd., known for its innovative solutions, has signed a strategic cooperation agreement with the Hungarian government. The aim of the agreement is to use Roche's value-based healthcare model to multiply the innovative and personalized therapies delivered to patients in a way that significantly reduces […]

Record Profit at Gedeon Richter Plc.

D&T
Nov 9, 2021

“Sales revenues in the first nine months were up on a year-on-year basis in most markets in both HUF and EUR terms, fueled by growth in the specialty portfolio, in particular higher Vraylar® and Evra® royalties. This broad-based strength in revenue performance was translated into a solid bottomline also ex-Vraylar®, despite higher spending on R&D […]

Two New EGIS Plants in Körmend

D&T
Oct 19, 2021

In order to increase their pharmaceutical production capacity, the French-owned Egis Pharmaceuticals has expanded its site in Körmend. With the investment of more than EUR 21.8 million, in addition to the new packaging factory, Egis has also established a plant with special know-how and technological needs, typically suitable for the production of oncology products; thereby […]

New Managing Director, New Venue at Roche Hungary

D&T
Oct 10, 2021

Important changes ahead in the life of the Swiss Roche Group's Hungarian subsidiary: a new managing director, Raffella Bondi has arrived at the helm of the company, which will continue its operations in the Budapest One office building. In parallel to the move, the pharmaceutical company is also moving to an agile organizational model. With […]

Less Profit but Still Good First Half Year for Richter

D&T
Aug 3, 2021

The decline in sales of some contraceptives, the absence of major acquisitions and the exchange rate movements reduced the profit at the Hungarian pharmaceutical company Gedeon Richter Plc. The after-tax profit of Gedeon Richter Plc. fell by 9.3% to HUF 54.9 billion in the first half of this year. Yet the company's revenue rose to […]

Gedeon Richter Divesting in the Republic of Moldova

D&T
Jun 21, 2021

The Hungarian pharmaceutical firm Gedeon Richter Plc. announced this Monday that it signed a multi-party agreement to divest its wholesale operation to Grin-Farm S.R.L. and its retail operations to BIRIVOFARM S.R.L., both in the Republic of Moldova. Richter as a majority owner of both the wholesale and the retail operations is entitled to approximately 62% […]

Richter Expands Cooperation to Japan and Taiwan

D&T
Jun 2, 2021

Gedeon Richter Plc. has announced that it extended its existing licensing agreement with AbbVie, originally dated 2004, for the development and commercialization of its own-developed molecule, cariprazine. The initial agreement covered the territories of the USA and Canada and was extended in 2019 to include certain countries in Latin America. The present agreement further expands […]

Gedeon Richter Contraceptive Approved by the EC

D&T
May 21, 2021

The Hungarian pharmaceutical Gedeon Richter Plc. has announced that the European Commission has granted approval for the marketing authorization of the novel combined oral contraceptive containing 15 mg estetrol and 3 mg drospirenone. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) […]

© Copyright 2022 Duax Kft. –  All rights reserved.
sun